Special Issue

Small-Molecule Modulators Targeting Emerging Therapeutic Pathways: Design, Synthesis and Biological Evaluation

Message from the Guest Editor

In the post-genomic era, the therapeutic modalities of human diseases have evolved dramatically. Smallmolecule modulators used to be the standard option for defined therapeutic pathways; however, antibodies, nucleotide-based drugs, and cell-based therapies are attracting increasing amounts of attention. Many novel therapeutic targets are emerging driven by advancements in biologic and clinical research. providing new opportunities for small-molecule modulators. In addition, specific cellular protein(s) can now be selectively degraded in the presence of rationally designed PROTACs and/or molecular glues, while small-molecule modulators of human immunity also show great therapeutic promises in human clinical trials. Notwithstanding, small-molecule modulators of enzymes are still a fruitful area of research delivering numerous marketed drugs. In view of the dynamic evolution of small-molecule modulators targeting emerging therapeutic pathways, this Special Issue welcomes original research concerning their design, synthesis and biological evaluation.

Guest Editor

Prof. Dr. Yujun Zhao State Key Laboratory of Drug Research and Small-Molecule Drug Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

Deadline for manuscript submissions

30 November 2024



Molecules

an Open Access Journal by MDPI

Impact Factor 4.2 CiteScore 7.4 Indexed in PubMed



mdpi.com/si/179531

Molecules MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 molecules@mdpi.com

mdpi.com/journal/

molecules





Molecules

an Open Access Journal by MDPI

Impact Factor 4.2 CiteScore 7.4 Indexed in PubMed



molecules



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Chemistry, Multidisciplinary) / CiteScore - Q1 (Chemistry (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2024).